Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis.

ABSTRACT: Cardiac amyloidosis is a restrictive cardiomyopathy that results from the deposition of misfolded light chain or transthyretin proteins, most commonly, in cardiac tissue. Traditionally, treatment options for light chain (AL) and transthyretin (ATTR) amyloidosis have been limited. However, there are now multiple novel therapeutics in development and several therapeutics recently approved that promise to revolutionize clinical management of AL and ATTR. Most of these agents disrupt specific stages of amyloidogenesis such as light chain or transthyretin protein production, formation of amyloidogenic intermediates, or amyloid fibril aggregation. Others aim to remove existing amyloid tissue deposits using monoclonal antibody technology. Although these advances represent an important step forwar

SUBMITTER: Zhang KW 

PROVIDER: S-EPMC6609907 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature